Urologie

Publikationen 2021-22

Heidegger I, Fotakis G, Offermann A, Goveia J, Daum S, Salcher S, Noureen A, Timmer-Bosscha H, Schäfer G, Walenkamp A, Perner S, Beatovic A, Moisse M, Plattner C, Krogsdam A, Haybaeck J, Sopper S, Thaler S, Keller MA, Klocker H, Trajanoski Z, Wolf D, Pircher A (2022): "Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer”, Mol Cancer 21:132.
Kafka M, Burtscher T, Fritz J, Schmitz M, Bektic J, Ladurner M, Horninger W, Heidegger I (2022): "Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir <0.05 ng/ml as marker for treatment response”, World J Urol, 2022.
Schaefer G, Bednarova N, Heidenreich A, Klocker H, Heidegger I (2021): "KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer”, Transl Androl Urol 10:3946-3952.
Steuber T, Heidegger I, Kafka M, Roeder M, Chun F, Preisser F, Palisaar RJ, Hanske J, Budaeus L, Schiess R, Keller T, Semjonow A, Hammerer P, Manka L, Ecke T, Schwentner C, Ohlmann C (2022): "PROPOSe: a real-life prospective study of Proclarix, a novel blood-based test to support challenging biopsy decision-making in prostate cancer”, Eur Urol Oncol 5:321-327.
Furlan T, Kirchmair A, Sampson N, Puhr M, Gruber M, Trajanoski Z, Santer FR, Parson W, Handle F, Culig Z (2021): "MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors”, Am J Pathol 191:1094-1107.
Offermann A, Kang D, Watermann C, Weingart A, Hupe MC, Saraji A, Stegmann-Frehse J, Kruper R, Schüle R, Pantel K, Taubert H, Duensing S, Culig Z, Aigner A, Klapper W, Jonigk D, Kühnel MP, Merseburger AS, Kirfel J, Sailer V, Perner S (2021): "Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases”, Carcinogenesis 42:1475-1484.
Vakhrusheva O, Erb HHH, Bräunig V, Markowitsch SD, Schupp P, Baer PC, Slade KS, Thomas A, Tsaur I, Puhr M, Culig Z, Cinati Jr. J, Michaelis M, Efferth T, Haferkamp A, Jüngel E (2022): "Artesunate inhibits the growth behavior of docetaxel-resistant prostate cancer cells”, Front Oncol 12:789284.
Muresan X, Slabakova E, Prochazkova J, Drapela S, Fedr R, Pickova M, Vacek O, Vichova R, Suchankova T, Bouchal J, Kurfurstova D, Kral M, Hulinova T, Sykora RP, Student V, Hejret V, van Weerden WM, Puhr M, Pustka V, Potesil D, Zdrahal Z, Culig Z, Soucek K (2022): "Toll-like receptor 3 overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis”, Am J Pathol 192:1321-1335.
Limberger T, Schlederer M, Trachtova K, Garces de los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J, Tichy B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer MS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, Kenner L (2022): "KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis”, Mol Cancer 21:89.
Ladurner M, Wieser M, Eigentler M, Seewald M, Dobler G, Neuwirt H, Kafka M, Heidegger I, Horninger W, Bektic J, Klocker H, Obrist P, Eder IE (2021): "Validation of cell-free RNA and circulating tumor cells for molecular marker analysis in metastatic prostate cancer”, Biomedicines 9:1004.
Kafka M, Gruber R, Neuwirt H, Ladurner M, Eder IE (2022): "Long-term treatment with simvastatin leads to reduced migration capacity of prostate cancer cells”, Biomedicines 11:29.
Keresztes D, Csizmarik A, Nagy N, Modos O, Fazekas T, Bracht T, Sitek B, Witzke K, Puhr M, Sevcenco S, Kramer G, Shariat S, Kuronya Z, Takacs L, Tornyi L, Lazar J, Hadaschik B, Laszik A, Szucs M, Nyiradi P, Szarvas T (2022): "Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer”, J Cell Mol Med 26:1332-1337.
Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmit W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A (2021): "MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer”, Nat Commun 12:5066.
Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, Schaeffer G, Brandt MP, Hoefer J, van der Pluijm G, Klocker H (2021): "Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer”, Oncogene 40:3087-3100.
Pardella E, Pranzini E, Nesi I, Parri M, Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi F, Cirri P, Caselli A, Puhr M, Klocker H, Serni S, Raugei G, Magherini F, Taddei M (2022): "Therapy-induced stromal senescence promoting aggressiveness of prostate and ovarian cancer”, Cells 11:4026.
Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH (2022): "Metabolic changes during prostate cancer development and progression”, J Cancer Res Clin Oncol, in press.
Csizmarik A, Keresztes D, Nagy N, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lazar J, Takacs L, Kramer G, Sevcenco S, Maj-Hes A, Juranyi Z, Hadaschik B, Nyirady P, Szarvas T (2022): "Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer”, Int J Cancer 151:1405-1419.
Kang J, La Manna F, Bonollo F, Sampson N, Alberts I L, Mingels C, Afshar-Oromieh A, Thalmann GN, Karkampouna S (2022): "Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer”, Cancer Lett 530:156-169.
Lindner AK, Furlan T, Orme JJ, Tulchiner G, Staudacher N, D'Andrea D, Culig Z, Pichler R (2022): "HUS1 as a Potential Therapeutic Target in Urothelial Cancer", J Clin Med 11:2208.